Furthermore, co-targeting of PAD2 and AR with the small molecule inhibitors Cl-amidine (PAD enzyme inhibitor) and enzalutamide (AR signalling inhibitor) was shown to have a synergistic effect on reducing tumour growth, as compared to the treatment of either compound alone in a prostate cancer mouse model [82]. The gene discussed is PADI2; the disease is prostate carcinoma.